PIK3CA mutations as prognostic factor in squamous cell lung carcinoma

McGowan, Marc; Hoven, Aleksandra Silye; Lund‐Iversen, Marius; Solberg, Steinar; Helland, Åslaug; Hirsch, Fred R.; Brustugun, Odd Terje

doi:10.1016/j.lungcan.2016.11.018

Cited by 35 publications

(30 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have found that TP53 gene mutations may generate the same results in patients with NSCLC (31–33). PIK3CA encodes the type I phosphatidylinositol-3-kinase p110 α catalytic subunit (34) and is important for the development of NSCLC. PIK3CA phosphorylates the EGFR bypass pathway, PI3K/AKT/mTOR, to activate downstream signaling that promotes the proliferation, survival, adhesion and differentiation of tumor cells (35).…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of KRAS/TP53/PIK3CA in non‑small cell lung cancer

Zhao

Han

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

The present study explored the association between KRAS proto-oncogene GTPase (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA) and tumor protein p53 (TP53) mutations, and the clinical features and survival prognosis in 50 patients with non-small cell lung cancer (NSCLC). The most common concurrent single gene mutation was TP53, followed by KRAS and PIK3CA . Co-existing mutations were found in 17 patients. KRAS, PIK3CA and TP53 mutations were associated with carbohydrate antigen 19-9 expression, invasive growth, vacuolar signs and margin lobulation on chest CT. The incidence of distant metastasis (bone and adrenal) with KRAS and TP53 mutations was greater than that of local metastasis (pleura). Patients with the wild-type genes experienced longer progression-free survival (PFS) times than those with KRAS, TP53, KRAS/TP53 or PIK3CA/TP53 mutations. Patients with KRAS/TP53 or PIK3CA/TP53 mutations experienced shorter PFS times than those with a single KRAS or TP53 mutation. KRAS, PIK3CA and TP53 mutations were associated with distant metastases and a poor prognosis. Patients with NSCLC should receive routine KRAS, PIK3CA and TP53 gene sequencing to determine mutations for the analysis of clinical characteristics and prognosis .

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of KRAS/TP53/PIK3CA in non‑small cell lung cancer

Zhao

Han

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Associations between PIK3CA mutations and outcomes have shown conflicting results in the literature. PIK3CA mutations have demonstrated association with improved overall survival in squamous cell lung cancer and breast cancer [6] , [7] yet decreased progression-free survival in lung adenocarcinoma [8] . In a study by Boros et al [9] , next generation sequencing was performed on 57 patients with locally advanced NSCLC for EGFR, KRAS, BRAF, PIK3CA, NRAS, and ALK with 1 patient (2%) expressing a PIK3CA mutation.…”

Section: Discussionmentioning

confidence: 99%

PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT)

Lockney

Yang

Barron

et al. 2017

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

show abstract

“…Based on previous studies, PIK3CA mutation occurred more in lung squamous cell carcinoma with a frequency of 11.4% [ 23 ] than in lung adenocarcinoma with a frequency of 2.8% [ 24 ]. The most common mutation hotspots of the PIK3CA gene are located in the helical domain, especially E545K and E542K on exon 9, and the less frequent mutation hotspots of PIK3CA are located in the kinase domain like H1047R on exon 20 [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Wang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Aim. To explore the clinicopathological and prognostic role of PIK3CA gene mutation and expression in non-small-cell lung cancer (NSCLC) patients. Methods. A systematic and comprehensive literature search was conducted through EMBASE (via OVID), Web of Science, and PubMed. Relative risks (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were combined to evaluate the relationship of the PIK3CA gene with clinicopathological parameters and the survival of NSCLC patients, respectively. Results. A total of 13 studies involving 3908 patients were analyzed in our study. Only lymph node metastasis status had an association with PIK3CA mutation (RR=2.823; 95% CI: 1.128-7.065; P=0.029). The results indicated that PICK3CA mutation was related with overall survival (OS) (HR=1.55; 95% CI: 1.13-2.13; P=0.007), progression-free survival (PFS) (HR=1.48; 95% CI: 1.06-2.08; P=0.023), and cancer-specific survival (CSS) (HR=2.63; 95% CI: 1.00-6.92; P=0.005). Furthermore, PIK3CA high expression was more prevalent in NSCLC patients with smoking history (RR=2.42; 95% CI: 1.04-5.61; P=0.040). However, no significant relation between PIK3CA expression and OS was found (HR=0.80; 95% CI: 0.58-1.12; P=0.193). Conclusion. PIK3CA mutation may affect lymph node metastasis and serve as a promising prognostic factor, and smoking may be related with PIK3CA high expression in NSCLC patients. However, more well-designed prospective researches are needed to verify the abovementioned findings.

show abstract

PIK3CA mutations as prognostic factor in squamous cell lung carcinoma

Abstract: Our results indicate that PIK3CA mutations may confer a survival advantage in early stage squamous cell lung cancers, but further work is needed to confirm this finding.

Cited by 35 publications

References 128 publications

Prognostic value of KRAS/TP53/PIK3CA in non‑small cell lung cancer

Prognostic value of KRAS/TP53/PIK3CA in non‑small cell lung cancer

PIK3CA mutation is associated with increased local failure in lung stereotactic body radiation therapy (SBRT)

Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About